Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment

Dow Jones

01/06

By Kelly Cloonan

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis.

The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months.

The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day.

The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 05, 2026 18:12 ET (23:12 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601853109"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601853109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601853109?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601853109","market":"fut","top_or_hot":-1,"title":"Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n</p>\n<p>\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n</p>\n<p>\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n</p>\n<p>\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 18:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Shares Rise on Plans to Share Trial Data for Plaque Psoriasis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 07:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n</p>\n<p>\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n</p>\n<p>\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n</p>\n<p>\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 18:12 ET (23:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601853109","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601853109","pubTimestamp":1767654720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis.The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months.The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day.The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc.","BK4007":"制药"},"translate_title":"Alumis计划分享斑块型银屑病治疗试验数据，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. \n\n\n  The stock rose 8.9% to $9.05 in after-hours trading on Monday. Through market close, shares have more than doubled in the past three months. \n\n\n  The biopharmaceutical company said it will report the data on Tuesday and host a conference call to discuss the results the same day. \n\n\n  The company had said in November it expected to share the topline results early in the first quarter. The data, as well as expected results from a trial evaluating the therapy in systemic lupus erythematosus, could validate envu's differentiated profile and unlock further opportunities across immune-mediated diseases, Alumis said at the time. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 18:12 ET (23:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}